急性心力衰竭诊断决策支持工具的开发与验证:系统综述、Meta分析与建模研究
该研究基于13个国家14项研究、10369例疑似急性心力衰竭患者的个体数据,评估NT-proBNP阈值的诊断性能并开发验证CoDE-HF决策支持工具。指南推荐的300 pg/mL排除阈值阴性预测值为94.6%,但阳性预测值在年龄亚组间差异明显;CoDE-HF在有和无既往心衰患者中均校准良好,曲线下面积分别为0.846和0.925。
要点
- 指南推荐的300 pg/mL排除阈值阴性预测值为94.6%(95%CI 91.9%至96.4%)。
- 年龄特异阳性阈值阳性预测值随年龄升高:<50岁61.0%、50-75岁73.5%、>75岁80.2%。
- CoDE-HF在无既往心衰患者中识别40.3%为低概率(阴性预测值98.6%)。
核心结论
- 在疑似急性心衰患者中,指南推荐的NT-proBNP诊断阈值在重要亚组间诊断性能差异明显。
- 结合NT-proBNP连续测量值与其他临床变量的CoDE-HF决策支持工具提供了更一致、准确和个体化的诊断方法。
研究设计与样本
- 个体患者水平数据Meta分析与建模研究,纳入13个国家14项研究,包括随机对照试验与前瞻性观察性研究。
- 共纳入10369例疑似急性心衰患者的个体数据,用于评估NT-proBNP阈值并开发验证CoDE-HF决策支持工具。
主要发现
- 43.9%(4549/10369)患者经裁定诊断为急性心衰,其中有既往心衰者73.3%(2286/3119),无既往心衰者29.0%(1802/6208)。
- 指南推荐的300 pg/mL排除阈值阴性预测值为94.6%(95%CI 91.9%至96.4%)。
- 采用年龄特异阳性阈值时,阳性预测值在<50岁、50-75岁、>75岁患者中分别为61.0%(95%CI 55.3%至66.4%)、73.5%(95%CI 62.3%至82.3%)、80.2%(95%CI 70.9%至87.1%)。
- CoDE-HF在有和无既往心衰患者中校准良好,曲线下面积分别为0.846(95%CI 0.830至0.862)和0.925(95%CI 0.919至0.932),Brier评分分别为0.130和0.099。
- 无既往心衰患者中,40.3%(2502/6208)被识别为低概率(阴性预测值98.6%,95%CI 97.8%至99.1%),28.0%(1737/6208)被识别为高概率(阳性预测值75.0%,95%CI 65.7%至82.5%)。
关键数值与推荐
- 指南推荐的NT-proBNP排除阈值为300 pg/mL,阴性预测值94.6%(95%CI 91.9%至96.4%)。
- 年龄特异阳性阈值下阳性预测值:<50岁61.0%(95%CI 55.3%至66.4%)、50-75岁73.5%(95%CI 62.3%至82.3%)、>75岁80.2%(95%CI 70.9%至87.1%)。
- CoDE-HF在有既往心衰患者中曲线下面积0.846(95%CI 0.830至0.862)、Brier评分0.130;无既往心衰患者中曲线下面积0.925(95%CI 0.919至0.932)、Brier评分0.099。
- 无既往心衰患者中低概率组占40.3%(2502/6208),阴性预测值98.6%(95%CI 97.8%至99.1%)。
- 无既往心衰患者中高概率组占28.0%(1737/6208),阳性预测值75.0%(95%CI 65.7%至82.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the diagnostic performance of N-terminal pro-B-type natriuretic peptide (NT-proBNP) thresholds for acute heart failure and to develop and validate a decision support tool that combines NT-proBNP concentrations with clinical characteristics. DESIGN: Individual patient level data meta-analysis and modelling study. SETTING: Fourteen studies from 13 countries, including randomised controlled trials and prospective observational studies. PARTICIPANTS: Individual patient level data for 10 369 patients with suspected acute heart failure were pooled for the meta-analysis to evaluate NT-proBNP thresholds. A decision support tool (Collaboration for the Diagnosis and Evaluation of Heart Failure (CoDE-HF)) that combines NT-proBNP with clinical variables to report the probability of acute heart failure for an individual patient was developed and validated. MAIN OUTCOME MEASURE: Adjudicated diagnosis of acute heart failure. RESULTS: Overall, 43.9% (4549/10 369) of patients had an adjudicated diagnosis of acute heart failure (73.3% (2286/3119) and 29.0% (1802/6208) in those with and without previous heart failure, respectively). The negative predictive value of the guideline recommended rule-out threshold of 300 pg/mL was 94.6% (95% confidence interval 91.9% to 96.4%); despite use of age specific rule-in thresholds, the positive predictive value varied at 61.0% (55.3% to 66.4%), 73.5% (62.3% to 82.3%), and 80.2% (70.9% to 87.1%), in patients aged <50 years, 50-75 years, and >75 years, respectively. Performance varied in most subgroups, particularly patients with obesity, renal impairment, or previous heart failure. CoDE-HF was well calibrated, with excellent discrimination in patients with and without previous heart failure (area under the receiver operator curve 0.846 (0.830 to 0.862) and 0.925 (0.919 to 0.932) and Brier scores of 0.130 and 0.099, respectively). In patients without previous heart failure, the diagnostic performance was consistent across all subgroups, with 40.3% (2502/6208) identified at low probability (negative predictive value of 98.6%, 97.8% to 99.1%) and 28.0% (1737/6208) at high probability (positive predictive value of 75.0%, 65.7% to 82.5%) of having acute heart failure. CONCLUSIONS: In an international, collaborative evaluation of the diagnostic performance of NT-proBNP, guideline recommended thresholds to diagnose acute heart failure varied substantially in important patient subgroups. The CoDE-HF decision support tool incorporating NT-proBNP as a continuous measure and other clinical variables provides a more consistent, accurate, and individualised approach. STUDY REGISTRATION: PROSPERO CRD42019159407.
引用
- Lee KK, Doudesis D, Anwar M, et al. Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ. 2022. PMID: 35697365. doi:10.1136/bmj-2021-068424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。